Despite the gain in PIK/Akt function, target-specific inhibitors demonstrate low clinical efficacy and adverse effects in clinical trials with GBM patients, probably due to a lack of selectivity and alteration of several downstream targets (NCT01349660 and NCT01339052). This evidence concerns the gene AKT1 and glioblastoma.